Jeffrey Shealy compensation by year
Aktis Oncology Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $470,730 |
| Bonus | $0 |
| Stock awards | $571,500 |
| Option awards | $0 |
| Non-equity incentive | $235,365 |
| Pension and deferred compensation | $0 |
| All other | $13,145 |
| Total | $1,290,740 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aktis Oncology, Inc. DEF 14A filed October 8, 2024, accession 0001213900-24-086050, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Aktis Oncology, Inc. filed document, accession 0001213900-24-086050. Every figure is read from that document and cited to the page and table it appears in. Filed October 8, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 120,000 | $15,600 | — |
| RSU | 80,000 | $10,536 | — |
| RSU | 40,000 | $5,268 | — |
| RSU | 30,000 | $3,951 | — |
| RSU | 20,000 | $2,634 | — |
| RSU | 50,000 | $1,500 | — |
| RSU | 6,000 | $790 | — |
| Option | 6,000 | — | $7.98 |
| Option | 30,000 | — | $10.15 |
| Option | 20,000 | — | $8.11 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Aktis Oncology, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Aktis Oncology’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Jeffrey Shealy · this page | Former Chief Executive Officer | $1,290,740 |
| David Aichele | Former EVP of Business Development | $787,872 |
| Kenneth Boller | Chief Financial Officer | $685,936 |
The full Aktis Oncology compensation record
free company briefThis page is one person within Aktis Oncology's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aktis Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.